Ipatasertib is a selective (against a panel of 230 kinases) and potent pan-Akt inhibitor (IC50s: Akt1 = 5 nM, Akt2 = 18 nM, Akt3 = 8 nM).1 It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.2 In clinical trials
Know who made it. See the evidence. Buy through one marketplace.
Ipatasertib is a selective (against a panel of 230 kinases) and potent pan-Akt inhibitor (IC50s: Akt1 = 5 nM, Akt2 = 18 nM, Akt3 = 8 nM).1 It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.2 In clinical trials
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
